Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
Cytosorbents Corporation develops blood purification technologies for life-threatening conditions in intensive care and cardiac surgery. Its lead product, CytoSorb®, is approved in the European Union, distributed internationally, and used for cytokine adsorption and CE-marked applications that include bilirubin, myoglobin, ticagrelor, and rivaroxaban removal; in the United States it has FDA Emergency Use Authorization for adult critically ill COVID-19 patients with respiratory failure and is not otherwise approved or cleared.
Company updates commonly address quarterly and annual results, gross margin and balance-sheet actions, product launches such as HotSwap™, distribution partnerships, clinical evidence for CytoSorb therapy, and regulatory work around the investigational DrugSorb®-ATR antithrombotic removal system. The product portfolio also includes ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, ContrastSorb, PuriFi®, and related blood purification technologies.
CytoSorbents (NASDAQ: CTSO) reported Q1 2026 revenue of $8.9 million, up 2% year-over-year, with a 69% gross margin. Operating loss improved to $3.0 million, while net loss increased to $5.1 million, mainly from non-cash foreign currency effects. Cash stood at $6.4 million, with approximately $1.1 million quarterly cash burn excluding restructuring.
The company cited 13% growth in direct sales territories outside Germany, benefits from a 10% prior headcount reduction, and continued progress toward operating cash flow breakeven in 2H 2026. It is preparing a new De Novo submission for DrugSorb-ATR for Brilinta, targeting late 2026 or early 2027, and assessing a parallel De Novo path for DOAC removal. New clinical and health-economic data support safety, bleeding reduction in CABG subpopulations, and cost-effectiveness in septic shock.
CytoSorbents (NASDAQ: CTSO) will report first quarter 2026 financial results and recent business highlights after market close on Wednesday, May 13, 2026. Management will host a live conference call, webcast presentation, and Q&A starting at 4:30 PM ET the same day.
Investors are advised to dial in ~10 minutes early. A recorded archive will be available on the company's Investor Relations website.
CytoSorbents (NASDAQ: CTSO) reported 2025 revenue of $37.1M, up 4% year-over-year, with full-year gross margin of 71% and operating loss improving to $14.7M. Total cash was $7.8M on December 31, 2025. Management implemented Q4 cost reductions and secured an additional $2.5M from an amended credit facility to bolster runway. The company is in ongoing FDA discussions about a new De Novo submission for DrugSorb-ATR following prior feedback and recent pivotal and registry publications supporting antithrombotic removal.
Clinical momentum includes >300,000 cumulative CytoSorb treatments, expanded real-world and trial data across sepsis, cardiogenic shock, cardiac surgery, and DrugSorb-ATR evidence.
CytoSorbents (NASDAQ: CTSO) announced three developments at ISICEM 2026: the immediate launch of HotSwap™ to enable faster adsorber exchanges, renewal of its exclusive Italian distribution with Aferetica, and new clinical data (COSMOS registry n=306 and multiple studies) strengthening CytoSorb® evidence.
Key clinical highlights include reductions in vasopressor needs, improved oxygenation, myoglobin declines in rhabdomyolysis, and a COVID-19 meta-analysis showing a mortality trend.
CytoSorbents (NASDAQ: CTSO) will report fourth quarter and full year results for the period ended December 31, 2025, on Wednesday, March 25, 2026. Management will host a live webcast with Q&A starting at 4:30 PM ET. Participants are advised to join ~10 minutes early. An archived recording will be available under Investor Relations.
CytoSorbents (NASDAQ: CTSO) reported preliminary, unaudited Q4 2025 revenue of approximately $9.2M and full‑year 2025 revenue of approximately $37.0M (≈4% growth vs. 2024). Q4 gross margin is expected to be 73%–75% and full‑year gross margin approximately 72%. The company surpassed 300,000 cumulative CytoSorb treatments. The pivotal STAR‑T study for DrugSorb‑ATR was accepted for publication and a Pre‑Submission meeting with the FDA is scheduled this month, with an anticipated De Novo filing by end‑Q1 2026 and a regulatory decision expected in mid‑2026. A November 13, 2025 credit amendment added $2.5M of cash and extended interest‑only terms; an additional $2.5M and further extension are conditional on FDA approval. Management expects near operating cash‑flow breakeven in Q1 2026 excluding restructuring payments.
CytoSorbents (NASDAQ: CTSO) announced a virtual fireside chat on December 15, 2025 where CEO Dr. Phillip Chan and CFO Peter J. Mariani will join D. Boral Capital to discuss recent company developments.
Key points highlighted include $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for DrugSorb-ATR with an FDA decision expected in mid-2026. The session will expand on Q3 results and near-term milestones shaping the company’s growth trajectory.
Event time: 11:00 AM – 12:00 PM EST, Dec 15, 2025. Registration via D. Boral Capital.
CytoSorbents (NASDAQ: CTSO) will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 12:30 PM GMT / 7:30 AM ET.
Management will also hold one-on-one investor meetings during the conference (November 17-20, 2025). A live webcast of the presentation is available via the company website under Events and Presentations, and a replay will be archived for up to 90 days. This release updates the company's November 11, 2025 announcement to add the November 18 presentation.
CytoSorbents (NASDAQ: CTSO) reported Q3 2025 revenue of $9.5M, up 10% year-over-year, with gross margin 70%. Operating loss improved to $2.9M and net loss was $3.2M ($0.05/share); adjusted net loss was $2.6M ($0.04/share). Cash and equivalents were $9.1M on Sept 30, 2025, proforma $11.6M assuming an additional $2.5M term loan.
The company amended its credit agreement to provide an immediate $2.5M term loan, extended interest-only to Dec 31, 2026, and issued 1,428,571 warrants at $0.70. Workforce reduction of ~10% and a restructuring charge up to $900k aim to reach operating cash-flow breakeven in Q1 2026. DrugSorb-ATR De Novo submission is planned in Q1 2026 with an anticipated decision by mid-2026.
CytoSorbents (NASDAQ: CTSO) said its CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Jefferies Global Healthcare Conference in London on November 18-19, 2025.
Management will participate in one-on-one investor meetings; investors can schedule meetings through the conference website. For investor queries, contact the company investor relations team at ir@cytosorbents.com.